J
Javier P. Gisbert
Researcher at Autonomous University of Madrid
Publications - 1076
Citations - 39753
Javier P. Gisbert is an academic researcher from Autonomous University of Madrid. The author has contributed to research in topics: Helicobacter pylori & Inflammatory bowel disease. The author has an hindex of 95, co-authored 990 publications receiving 33726 citations. Previous affiliations of Javier P. Gisbert include Services Hospital & University of Alcalá.
Papers
More filters
Journal ArticleDOI
Outcome after a dose “de-intensification” strategy with anti-TNF drugs in patients with Crohn's disease
María Chaparro,Manuel Barreiro-de Acosta,Esther Garcia-Planella,Eugeni Domènech,Fernando Bermejo,Xavier Calvet,María Dolores Martín Arranz,David Monfort,Javier P. Gisbert +8 more
TL;DR: Evaluating the long-term durability of remission after stepping down anti-TNF therapy found that after only 7 months of follow-up, one-third of the CD patients who received "de-intensification" therapy lost response; of these, two-thirds did not achieve response after subsequent "re-intENSification".
Journal ArticleDOI
Efecto de la erradicación de Helicobacter pylori sobre las lesiones histológicas de la mucosa gástrica a lo largo de 18 meses
TL;DR: La erradicacion de H. pylori se asocia con una mejoria histologica de the mucosa gastrica que, aunque comienza a producirse ya en un momento precoz, continua a lo largo of 18 meses despues del tratamiento.
Journal ArticleDOI
Su1172 Non-Bismuth Quadruple (Concomitant) Therapy for Eradication of H. pylori: Standard vs. Optimized (14-Day, High-Dose PPI) Regimen
Javier P. Gisbert,Javier Molina-Infante,Yamal Harb,Fernando Bermejo,Ines Modolell,Angeles Perez Aisa,Mercè Barenys,Rosario Anton,Jesus Barrio,Juan Ortuño,Luis Rodrigo,Pedro Almela,Liliana Pozzati,A. Tomás,Alain Huerta,Javier Alcedo,Alicia Algaba,Nuria Fernandez Moreno,Miguel Fernandez Bermejo,Alicia C Marin,Adrian G. McNicholl +20 more
TL;DR: The most effective second-line treatments after the failure of a first-line therapy with PPI, amoxicillin and clarithromycin in H. pylori eradication are the metronidazole-amoxicillin-PPI or a 10 days levofloxacin-am toxicillin- PPI therapy.
Journal Article
[Helicobacter pylori and non-ulcer dyspepsia: a pending matter].
Journal ArticleDOI
Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers
Míriam Mañosa,M. Chaparro,Alba Juan Juan,C Arajol,Ignacio Alfaro,Miguel Minguez,B Velayos,José Manuel Benítez,Francisco Mesonero,Beatriz Sicilia,Y Zabana,Albert Villoria,Javier P. Gisbert,E. Domènech,Eneida registry by Geteccu +14 more
TL;DR: In patients with IBD and a history of cancer not related to immunosuppression, the use of IMTs is not associated with an increased risk of new or recurrent cancers even when IMTs are started early after cancer diagnosis.